< Back to previous page
Publication
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions
Journal Contribution - Journal Article
Aims: The vascular endothelial growth factor homologue placental growth factor (PlGF) is a
pleiotropic cytokine, with a pro-inflammatory activity. Previous gene-inactivation studies
revealed that loss of PlGF delays atherosclerotic lesion development and inhibits macrophage
infiltration, but the activity of an anti-PlGF antibody (aPlGF mAb) has not been evaluated yet.
Methods and Results: We characterized the potential of short-term delivery of aPlGF mAb in
inhibiting lesion development in ApoE-deficient mice (apoE-/-) and in CD4:TGFßRIIDN x apoE-/-
mice, a more severe atherosclerosis model. Short-term treatment of aPlGF mAb reduces
early atherosclerotic plaque size and inflammatory cell infiltration in the lesion.
Conclusions: These pharmacological aPlGF mAb results confirm previous genetic evidence
that inhibition of PlGF slows down early atherosclerotic lesion development. Furthermore, the
phenocopy of genetic and pharmacological loss-of-function strategies underscores that
aPlGF acts by selectively neutralizing PlGF.
Journal: CARDIOVASCULAR RESEARCH
ISSN: 0008-6363
Issue: 1
Volume: 86
Pages: 29 - 36
Publication year:2010
BOF-keylabel:yes
IOF-keylabel:yes
BOF-publication weight:6
CSS-citation score:2
Authors:International
Authors from:Private, Higher Education
Accessibility:Closed